Muskoka Algonquin Healthcare and Huntsville Hospital Foundation are pleased to unveil a new, state-of-the-art Bone Mineral ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after ...

Supplementation with cholecalciferol 1000 IU/day during pregnancy is associated with greater offspring bone mineral density during childhood.

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Patients with cystic fibrosis (CF) experience significant bone mineral density (BMD) loss at a younger age than those without the disease, with greater decline observed among individuals with ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Shares of Amgen fell as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Lung transplant patients should undergo annual bone health screenings using dual-energy X-ray absorptiometry for the first ...